ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval

Nicole DeFeudis

Editor

When ImmunoGen’s lead antibody-drug conjugate flunked a Phase III study in ovarian cancer a couple years ago, the company clung to hope that it would …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

FDA lifts hold on Entrada's Duchenne drug after two years

How AI can address ongoing challenges in the life sciences industry

Im­muno­Gen touts a PhI­II come­back in ovar­i­an can­cer, eye­ing a 2022 ac­cel­er­at­ed ap­proval

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval